Collplant Holdings (CLGN) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CollPlant Biotechnologies reported Q1 2024 financial results, noting a net loss increase and a cash balance of $23.2 million. The company highlighted its advancements in regenerative breast implants and ESG commitments, alongside a patent grant for its photocurable dermal filler product. Ongoing large-animal trials and development partnerships, such as with AbbVie, signal CollPlant’s continued innovation in regenerative and aesthetic medicine.
For further insights into CLGN stock, check out TipRanks’ Stock Analysis page.
